

CITATION REPORT

List of articles citing

The Prospective Cardiovascular Mnster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease

DOI: 10.1016/0002-8703(88)90220-7
American Heart Journal, 1988, 116, 1713-24.

Source: <https://exaly.com/paper-pdf/19724067/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
375	Summary and closing remarks. <i>American Heart Journal</i> , 1988 , 116, 1838-1840	4.9	
374	Diabetes mellitus and hypertension in the elderly: concomitant hyperlipidemia and coronary heart disease risk. 1989 , 63, 33H-37H		54
373	Clinical pharmacotherapeutics of doxazosin. 1989 , 87, 2S-11S		13
372	Beneficial effects of indapamide on lipoproteins and apoproteins in ambulatory hypertensive patients. 1990 , 65, 77H-80H		7
371	Hyperlipidemia in diabetes mellitus. 1990 , 6, 47-61		79
370	Abstracts from 17th AADE Annual Meeting: From the Editor of the 1990 Annual Meeting Proceedings. 1990 , 16, 321-337		
369	A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. <i>Circulation</i> , 1990 , 82, 848-55	16.7	271
368	Hyperlipidaemia in diabetes. 1990 , 4, 743-75		75
367	Hypertriglyceridaemia and its influence on low density lipoprotein regulation of cellular cholesterol synthesis: a comparison between hypertriglyceridaemic diabetic and non-diabetic patients. 1991 , 8, 745-51		3
366	Interaction of non-esterified fatty acid and insulin in control of triacylglycerol secretion by Hep G2 cells. 1991 , 280 (Pt 1), 99-104		69
365	The role of the cholesteryl ester transfer protein in lipoprotein metabolism. 1991 , 7, 139-53		26
364	Prevalence of diabetes mellitus and impaired glucose tolerance in the middle-aged population of three areas in Finland. 1991 , 20, 1010-7		42
363	Effect of diuretics on the plasma lipid profile. 1992 , 13 Suppl G, 61-7		38
362	Greater effect of glycemia on incidence of hypertension in women than in men. 1992 , 15, 1277-84		53
361	Lp(a) concentrations in NIDDM. 1992 , 41, 1267-72		84
360	Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. 1992 , 41 Suppl 2, 12-7		108
359	A double blind study of the effect of acipimox on serum lipids, blood glucose control and insulin action in non-obese patients with type 2 diabetes mellitus. 1992 , 9, 908-14		29

358	Control of Hep G2-cell triacylglycerol and apolipoprotein B synthesis and secretion by polyunsaturated non-esterified fatty acids and insulin. 1992 , 288 (Pt 1), 101-7	49
357	The relation between serum insulin levels and 8-year changes in lipid, lipoprotein, and blood pressure levels. 1992 , 136, 12-22	74
356	Effect of gemfibrozil on intermediate-density lipoproteins in NIDDM patients. A retrospective study. 1992 , 15, 146-7	2
355	Lipid metabolism in type II diabetes. 1992 , 92, 105-6, 111-3	4
354	Swiss hypertension treatment programme with verapamil and/or enalapril in diabetic patients. 1992 , 44 Suppl 1, 74-84	4
353	Acute myocardial infarction in the diabetic patient: pathophysiology, clinical course and prognosis. 1992 , 20, 736-44	232
352	Insulin treatment, endogenous insulin concentration, and ECG abnormalities in diabetic Pima Indians. Cross-sectional and prospective analyses. 1992 , 41, 1141-50	56
351	Lack of change of lipoprotein (a) concentration with improved glycemic control in subjects with type II diabetes. 1992 , 41, 116-20	79
350	Lack of association between lipoprotein (a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin Epidemiologic Study of Diabetic Retinopathy. 1992 , 41, 194-7	90
349	The importance of triglycerides: results from the Prospective Cardiovascular Münster (PROCAM) Study. 1992 , 8 Suppl 1, 99-103	45
348	Lipoprotein (a), low-density, intermediate-density lipoprotein, and blood pressure in a young male population. 1993 , 71, 145-9	8
347	Gender differences in a type 2 (non-insulin-dependent) diabetic population with respect to apolipoprotein E phenotype frequencies. <i>Diabetologia</i> , 1993 , 36, 229-33	10.3 17
346	The case for metabolic hypertension: is it time to restructure the hypertension paradigm?. 1993 , 36, 1-38	16
345	Early extracoronary atherosclerosis and coronary heart disease risk factors in a sample of civil servants in southern Italy. 1993 , 102, 1-7	7
344	Effects of doxazosin, an alpha 1-adrenergic inhibitor, on plasma lipid and lipoprotein levels, low density lipoprotein metabolism and cholesterol absorption in cynomolgus monkeys. 1993 , 103, 255-66	6
343	Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson). 1993 , 3, 131-9	2
342	Triglycerides and disease. 1993 , 69, 679-95	6
341	Development of macrovascular diseases in NIDDM patients in northern Taiwan. A 4-yr follow-up study. 1993 , 16, 137-43	31

340	Lipoprotein(a) and diabetes. An update. 1993 , 16, 835-40		55
339	Serum Cholesterol Lowering by Dietary Sitostanol Is Associated with Reduced Absorption and Synthesis of Cholesterol and Decreased Transport of LDL Apoprotein B in Men with Type II Diabetes. 1993 , 57-59		
338	Multivariate analysis of the insulin resistance syndrome in women. 1994 , 14, 1940-5		131
337	DNA variants at the LPL gene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a Welsh population. 1994 , 14, 1090-7		114
336	Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. <i>Diabetologia</i> , 1994 , 37, 889-96	10.3	77
335	Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. <i>Diabetologia</i> , 1994 , 37, 585-91	10.3	50
334	Simvastatin in non-insulin-dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. 1994 , 23, 111-9		44
333	Diabetic postprandial triglyceride-rich lipoproteins increase esterified cholesterol accumulation in THP-1 macrophages. 1994 , 43, 1063-72		23
332	Simvastatin in the treatment of patients with hypercholesterolemia and associated coronary heart disease risk factors: An Italian multicenter study. 1994 , 55, 786-796		
331	Treatment of non-insulin-dependent diabetes mellitus and its complications. A state of the art review. 1994 , 4, 470-91		15
330	Lipoprotein disorders in diabetes mellitus. 1994 , 78, 143-61		68
329	Hypertension: are beta-blockers and diuretics appropriate first-line therapies?. 1994 , 28, 617-25		6
328	Severity of Coronary Atherosclerosis in Relation to Hypertension and Dyslipidemia. 1995 , 5, 17-22		1
327	5.2 Dyslipoproteinemia.		
326	Treating hyperlipidemia in the elderly. 1995 , 46, 1075-83		12
325	Internal Thoracic Artery Flow in Diabetic Patients. 1995 , 29, 83-89		
324	Serum lipids and lipoprotein(a) concentrations in Chinese NIDDM patients. Relation to metabolic control. 1995 , 18, 1191-4		26
323	Mortality from coronary heart disease and stroke for six ethnic groups in California, 1985 to 1990. 1995 , 5, 432-9		62

322	Lipids and atherosclerosis. 1995 , 16, 509-710	10
321	Lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus and borderline hyperglycemia: a population-based study. 1995 , 44, 1293-7	6
320	Factors affecting lipoprotein lipase in hypertensive patients. 1995 , 44, 712-8	12
319	Undiagnosed glucose intolerance in the community: the Isle of Ely Diabetes Project. 1995 , 12, 30-5	139
318	Abnormal cholesterol distribution among lipoprotein fractions in normolipidemic patients with mild NIDDM. 1995 , 118, 111-22	27
317	Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. 1995 , 346, 869-72	317
316	Metabolic manifestations of low-dose diuretics. 1996 , 101, 71S-82S	52
315	Myocardial alterations in diabetes and hypertension. 1996 , 31 Suppl, S133-42	30
314	Dyslipidemia in diabetes mellitus. 1996 , 33, 1-14	36
313	Hypercoagulability and high lipoprotein(a) levels in patients with type II diabetes mellitus. 1996 , 120, 7-14	60
312	Insulin resistance and cardiovascular complications in patients with essential hypertension. 1996 , 9, 1165-71	31
311	Diabetic and hypertensive heart disease. 1996 , 125, 304-10	116
310	Cardiovascular risk factors and the prediabetic syndrome. 1996 , 28, 363-70	23
309	Electronegative low density lipoprotein subform is increased in patients with short-duration IDDM and is closely related to glycaemic control. <i>Diabetologia</i> , 1996 , 39, 1469-76	10.3 66
308	Hypertriglyceridemia and its Metabolic Consequences as a Risk Factor for Atherosclerotic Cardiovascular Disease in Non-Insulin-Dependent Diabetes Mellitus. 1996 , 12, 37-56	55
307	Triglyceride-rich lipoproteins in non-insulin-dependent diabetes mellitus: post-prandial metabolism and relation to premature atherosclerosis. 1996 , 26, 89-108	101
306	Effectiveness versus efficacy of treatment of hypertension for stroke prevention. 1996 , 46, 301-7	47
305	Assessing the independent effect of dietary counseling and hypolipidemic medications on serum lipids. 1996 , 47, 831-40	12

304	The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease. 1997 , 20, 469-71	69
303	The role of insulin and proinsulin in the regulation of triglyceride metabolism. 1997 , 105 Suppl 2, 29-35	1
302	Lipoprotein(a) in android obesity and NIDDM. 1997 , 20, 1693-6	12
301	Epidemiology of hypertension and insulin resistance syndrome. 1997 , 15, S25-30	22
300	Role of Fatty Acids in the Pathogenesis of Insulin Resistance and NIDDM. 1997 , 46, 3-10	1235
299	Insulin resistance implications for type II diabetes mellitus and coronary heart disease. 1997 , 103, 152-62	172
298	Combination therapy and target organ protection in hypertension and diabetes mellitus. 1997 , 10, 198S-201S	13
297	Lack of association of lipoprotein (a) with coronary heart disease in Spaniard type 2 diabetic patients. 1997 , 35, 135-41	6
296	Progress in population analyses of the insulin resistance syndrome. 1997 , 827, 1-12	15
295	The prediabetic problem: development of non-insulin-dependent diabetes mellitus and related abnormalities. 1997 , 11, 69-76	18
294	Determinants of coronary vascular disease in patients with type II diabetes mellitus and their therapeutic implications. 1997 , 20, 433-40	23
293	Acute Coronary Syndromes: Molecular Basis for Cardiac Risk Factors. 1997 , 4, 167-175	3
292	Glycosylation enhances oxygen radical-induced modifications and decreases acetylhydrolase activity of human low density lipoprotein. 1997 , 92, 96-105	33
291	Effect of the calcium channel antagonist nitrendipine on lipoprotein lipase and hepatic lipase in the normal rat. 1998 , 351, 357-61	2
290	Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia. 1998 , 20, 477-85	5
289	A middle-aged man presents with a number of risk factors. 1998 , 2, 158-163	
288	Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. 1998 , 140, 199-270	422
287	Birth weight, adult weight, and girth as predictors of the metabolic syndrome in postmenopausal women: the Rancho Bernardo Study. 1998 , 21, 1652-8	111

286	Development of the multiple metabolic syndrome: an epidemiologic perspective. 1998 , 20, 157-72		279
285	Incidence and risk factors for stroke in an occupational cohort: the PROCAM Study. Prospective Cardiovascular Muenster Study. 1998 , 29, 1562-6		58
284	Short-term efficacy and tolerability of combination therapy with lovastatin and acipimox in Chinese patients with type 2 diabetes mellitus and mixed dyslipidemia. 1998 , 38, 912-7		3
283	Are apolipoproteins A and B better than lipoproteins for assessing risk of obstructive coronary heart disease?. <i>Arquivos Brasileiros De Cardiologia</i> , 1999 , 72, 657-68	1.2	3
282	The KID Study VI: diabetic complications and associated diseases in younger type 2 diabetics still performing a profession. Prevalence and correlation with duration of diabetic state, BMI and C-peptide. 1999 , 107, 435-41		10
281	Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry. <i>Circulation</i> , 1999 , 100, 475-82	16.7	123
280	Effects of diabetes mellitus on patients with acute intermittent porphyria. 1999 , 245, 193-7		11
279	Baseline characteristics of the study population in the Diabetes Atherosclerosis Intervention Study (DAIS). World Health Organization Collaborating Centre for the Study of Atherosclerosis in Diabetes. 1999 , 84, 1004-10		23
278	Pharmacologic therapy for type 2 diabetes mellitus. 1999 , 131, 281-303		787
277	[Primary nutritional and drug prevention of atherosclerosis]. 1999 , 20 Suppl 3, 360s-370s		2
276	Urinary excretion of apolipoprotein(a) fragments in type 1 diabetes mellitus patients. 1999 , 48, 369-72		7
275	Influence of diabetes mellitus on early and late outcome after coronary artery bypass grafting. 1999 , 67, 1045-52		308
274	Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. 1999 , 34, 146-54		572
273	Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. 1999 , 8, 1683-1707		96
272	The role of protein kinase C in the development of the complications of diabetes. 2000 , 60, 149-93		46
271	An application of apo(a) isoforms for the clinical assessment of Lp(a). 2000 , 14, 53-8		2
270	Trends in lipid levels and hypercholesterolemia in hypertensive and normotensive finnish adults from 1982 to 1997. 2000 , 247, 53-62		17
269	Presence of Fetal RNA in Maternal Plasma. 2000 , 46, 1832-1834		225

268	Comparison of Three Methods for Measuring LDL Resistance against Copper-induced Oxidation. 2000 , 46, 291-294	9
267	Inaccuracy of Calculated LDL-Cholesterol in Type 2 Diabetes: Consequences for Patient Risk Classification and Therapeutic Decisions. 2000 , 46, 1830-1832	19
266	Point-of-Care Testing of Triglycerides: Evaluation of the Accutrend Triglycerides System. 2000 , 46, 287-291	42
265	Effect of hypertension on the development of diabetic cardiomyopathy. 2000 , 78, 791-798	12
264	Long-term prevention of ischaemic stroke and stroke recurrence. 2000 , 98, 83-96	8
263	[Dyslipidemia and arterial hypertension: association or coincidence?]. 2000 , 115, 58-9	1
262	Effects of combination therapy with estrogen plus simvastatin on lipoprotein metabolism in postmenopausal women with type IIa hypercholesterolemia. 2000 , 150, 103-111	16
261	Apo(B)-dependent dyslipidemic phenotypes in type 1 diabetic patients. 2001 , 12, 496-502	1
260	A double-blind trial on the effects of atorvastatin on glycemic control in Japanese diabetic patients with hypercholesterolemia. 2001 , 312, 41-7	20
259	Subgrupos especiales en cardiopatía isquémica. el paciente diabético. el paciente anciano. cardiopatía isquémica en la mujer. el paciente no revascularizable de forma convencional. 2001 , 8, 2391-2403	
258	Hipertensión arterial en el paciente dislipémico. 2001 , 13, 179-194	1
257	The Pancreas and Lipoprotein Metabolism. 2001 , 675-706	
256	Dyslipidaemia and diabetes. 2001 , 18, 201-207	10
255	Treating lipid abnormalities in patients with type 2 diabetes mellitus. 2001 , 88, 37N-40N	31
254	Cholesterol and glycemic effects of Niaspan in patients with type 2 diabetes. 2001 , 21, 1473-8	21
253	Effect of glycemic optimization on electronegative low-density lipoprotein in diabetes: relation to nonenzymatic glycosylation and oxidative modification. 2001 , 86, 3243-9	55
252	Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. 2002 , 13, 229-36	184
251	Hypertension and coronary heart disease. 2002 , 16 Suppl 1, S61-3	57

250	Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. 2002 , 87, 3227-35	115
249	Serum cholesterol affects blood pressure regulation. 2002 , 16, 337-43	27
248	Mechanisms of obesity-associated cardiovascular and renal disease. 2002 , 324, 127-37	276
247	Modificaci3n de los factores de riesgo en el paciente arterioscler3tico joven: mecanismos implicados. 2002 , 54, 174-181	
246	[Prognosis of diabetic patients with ischemic cardiopathy]. 2002 , 55, 751-62	8
245	Hipertensi3n arterial en el paciente dislipid3mico. 2002 , 19, 222-237	
244	. 2002 ,	10
243	Cardiac Complications and Management. 577-605	
242	The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. 2002 , 16, 24-8	67
241	Where thiazolidinediones will fit. 2002 , 18 Suppl 2, S30-5	6
240	The influence of cardiovascular disease on quality of life in type 2 diabetics. 2002 , 11, 249-61	46
239	Impact of the obesity epidemic on hypertension and renal disease. 2003 , 5, 386-92	82
238	[End-organ damage in hyperlipidemias]. 2003 , 44, 831-2, 835-9	1
237	Prediction of cardiovascular risk in people with diabetes. 2003 , 20, 515-27	19
236	The renin-angiotensin system and the long-term complications of diabetes: pathophysiological and therapeutic considerations. 2003 , 20, 607-21	60
235	Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. 2003 , 171, 1-13	163
234	European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003 , 10, S1-S78	44
233	Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor. 2003 , 115, 122-8	6

232	Non-HDL cholesterol and apolipoprotein B in the dyslipidemic classification of type 2 diabetic patients. 2003 , 26, 2048-51	43
231	The Metabolic Syndrome: Targeting Dyslipidaemia to Reduce Coronary Risk. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003 , 10, 121-128	20
230	Confirmed locus on chromosome 11p and candidate loci on 6q and 8p for the triglyceride and cholesterol traits of combined hyperlipidemia. 2003 , 23, 2070-7	44
229	CHD prevention: the importance of identifying dyslipidaemia. 2003 , 12, 950-8	
228	Thinking intelligently about therapy of atherosclerosis. 2003 , 10, 429-37	2
227	. 2003 , 10, 121-128	62
226	Obesity-associated hypertension and kidney disease. 2003 , 12, 195-200	121
225	Lipid abnormalities and renal disease: is dyslipidemia a predictor of progression of renal disease?. 2003 , 325, 340-8	44
224	Obesity as the core of the metabolic syndrome and the management of coronary heart disease. 2004 , 20, 295-304	86
223	Diabetes and cardiovascular risk evaluation and management in primary care: progress and unresolved issues - rationale for a nationwide primary care project in Germany. 2004 , 112, 157-70	10
222	Dyslipidemia and the metabolic syndrome. 2004 , 27, 3009-16	16
221	Diagnosis, epidemiology and pathogenesis of diabetes mellitus: an update for psychiatrists. 2004 , 47, S55-63	30
220	Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. 2004 , 89, 6068-76	231
219	Work-site hypertension prevalence and control in three Central European Countries. 2004 , 18, 581-5	11
218	Pathophysiology and long-term management of the metabolic syndrome. 2004 , 12 Suppl, 174S-80S	18
217	PPAR- γ receptor agonists-a review of their role in diabetic management in Trinidad and Tobago. 2004 , 263, 189-210	3
216	Plasma homocysteine, MTHFR C677T, CBS 844ins68bp, and MTHFD1 G1958A polymorphisms in spontaneous cervical artery dissections. 2004 , 251, 1242-8	47
215	Diabetic dyslipidaemia: past, present and future. 2004 , 21, 78-85	2

214	Alteraciones metabólicas y enfermedad cardiovascular. 2004 , 21, 331-333		
213	The impact of vitamin and/or mineral supplementation on lipid profiles in type 2 diabetes. 2004 , 65, 21-8		47
212	In vivo oxidizability of LDL in type 2 diabetic patients in good and poor glycemic control. 2004 , 173, 103-7		9
211	The influence of type 2 diabetes mellitus in patients undergoing coronary artery bypass graft surgery: an 8-year prospective cohort study. 2004 , 126, 1789-95		36
210	Nutraceuticals. 2004 ,		
209	Calculating global risk: the key to intervention. 2005 , 7, F9-F14		5
208	Clinical features of sudden sensorineural hearing loss in diabetic patients. 2005 , 115, 1676-80		42
207	[Cardiovascular high-risk constellations in primary care. DETECT Study 2003]. 2005 , 48, 1374-82		9
206	The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity. <i>Diabetologia</i> , 2005 , 48, 2162-9	10.3	40
205	Koronare Herzerkrankung: Klinik und Diagnostik. 2005 , 207-229		
204	11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice. 2005 , 202, 517-27		330
203	Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?. 2005 , 3, 911-24		44
202	Protease inhibitors in spontaneous cervical artery dissections. 2005 , 36, 9-13		24
201	Cardiovascular risk factors in primary care: methods and baseline prevalence rates--the DETECT program. 2005 , 21, 619-30		83
200	PPARgamma and atherosclerosis. 2005 , 21 Suppl 1, S13-20		59
199	Prevention of cardiovascular events in elderly people. 2005 , 22, 859-76		56
198	2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 28, 1462-536		1418
197	Grado de control de la dislipemia en los pacientes españoles asistidos en atención primaria. Estudio LIPICAP. 2006 , 18, 226-238		2

196	Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular MÜNster (PROCAM) study. 2006 , 16, 13-21	176
195	Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review. 2006 , 1, 129-47	42
194	Low-density lipoproteins are more electronegatively charged in type 1 than in type 2 diabetes mellitus. 2006 , 41, 529-33	7
193	Coronary heart disease in women: why the disproportionate risk?. 2006 , 6, 22-8	12
192	The metabolic syndrome: prevalence, CHD risk, and treatment. 2006 , 20, 121-32	59
191	Development of bioactive substances for functional foods--scientific and other aspects. 2006 , 59, 171-181	1
190	Prevalence of metabolic syndrome in young patients with acute MI: does the Framingham Risk Score underestimate cardiovascular risk in this population?. 2006 , 3, 103-7	28
189	The state of lipid control in patients with diabetes in a public health care centre. 2007 , 19, 16-21	6
188	Relationship between phytosterol levels and components of the metabolic syndrome in the PROCAM study. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007 , 14, 208-14	16
187	Chapter 1: Introduction. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2007 , 14, S2-S113	
186	2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 25, 1105-87	3825
185	The topography of aortic atherosclerosis enhances its precision as a predictor of stroke. 2007 , 83, 2087-92	39
184	Hypertension in people with diabetes in sub-Saharan Africa: revealing the hidden face of the iceberg. 2007 , 77, 293-9	39
183	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. 2007 , 194, 1-45	190
182	2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2007 , 16, 135-232	247
181	European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i>	309
180	European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). 2007 , 28, 2375-414	1029
179	Renin-angiotensin-aldosterone system intervention in the cardiometabolic syndrome and cardio-renal protection. 2007 , 1, 27-35	17

178	[Prevalence of the metabolic syndrome in Spanish patients with established cardiovascular disease: CLYDIA study]. 2007 , 128, 407-13	10
177	[ESH/ESC 2007 Guidelines for the management of arterial hypertension]. 2007 , 60, 968.e1-94	29
176	Non-HDL cholesterol versus Apolipoprotein B in the identification of dyslipidemic phenotypes associated with cardiovascular risk in type 2 diabetic dyslipoproteinemia. 2007 , 1, 29-36	4
175	Lifestyle and outcome among patients with type 2 diabetes. 2007 , 1303, 160-171	6
174	Pathophysiology of Obesity-Induced Hypertension and Target Organ Damage. 2007 , 447-468	11
173	Risk factors of atherosclerotic diseases. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerosis cardiovascular diseases for Japanese. 2007 , 14, 267-77	44
172	Effect of telmisartan in hypertensive patients with diabetes mellitus. 2007 , 53, 251-256	
171	Management of coronary artery disease in patients with type 2 diabetes mellitus. 2007 , 9, 264-71	6
170	Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. 2008 , 45, 23-30	22
169	Guías de prática clínica sobre prevenção de la enfermedad cardiovascular: versión resumida. 2008 , 61, 82.e1-82.e49	14
168	s-ICAM-1 and s-VCAM-1 in healthy men are strongly associated with traits of the metabolic syndrome, becoming evident in the postprandial response to a lipid-rich meal. 2008 , 7, 32	25
167	Hypertension and diabetes. 2008 , 45, 82-106	42
166	Fatores de risco para acidente vascular encefálico após cirurgia de revascularização do miocárdio. <i>Arquivos Brasileiros De Cardiologia</i> , 2008 , 91,	1.2
165	The prevalence of the metabolic syndrome components and their combinations in men and women with acute ischemic syndromes. 2008 , 44, 521	8
164	Prevalence of cardiovascular risk factors in an unselected Italian population. Results of the Cardiolab Project 2004-2008. 2009 , 64, 771-8	7
163	Valsartan combination therapy in the management of hypertension - patient perspectives and clinical utility. 2009 , 2, 39-54	4
162	Clinical Prediction Models. 2009 ,	903
161	Should we treat prehypertension in diabetes? What are the cons?. 2009 , 32 Suppl 2, S280-3	4

160	The diabetic, hypertensive heart: epidemiology and mechanisms of a very high-risk situation. 2009 , 23, 709-17	10
159	Association of oxidative stress and paraoxonase status with PROCAM risk score. 2009 , 42, 617-23	10
158	Temporal association of elevated C-reactive protein and periodontal disease in men. 2009 , 80, 734-9	19
157	The endocannabinoid system and cardiometabolic risk: effects of CB1 receptor blockade on lipid metabolism. 2009 , 131, 305-12	7
156	Linking diabetes and atherosclerosis. 2009 , 4, 603-624	6
155	Family History and Preclinical Atherosclerosis. 2009 , 5, 94-101	
154	Diabète et hypertension artfielle. 2010 , 7, 1-11	
153	Effects of individual risk factors on the residual risk of cardiovascular events in a population of treated Chinese patients with hypertension: data from the Felodipine Event Reduction (FEVER) study. 2010 , 28, 2016-25	13
152	Blood Lipid Abnormalities. 2010 , 136-141	
151	Coestilan monotherapy significantly improves glycaemic control and LDL cholesterol levels in patients with type 2 diabetes: a randomized double-blind placebo-controlled study. 2010 , 12, 246-51	21
150	Effect of corosolic acid on dietary hypercholesterolemia and hepatic steatosis in KK-Ay diabetic mice. 2010 , 31, 213-8	21
149	Cardiac risk stratification: role of the coronary calcium score. <i>Vascular Health and Risk Management</i> , 2010 , 6, 603-11	4.4 21
148	High-density lipoprotein cholesterol increase and non-cardiovascular mortality: a meta-analysis. 2010 , 96, 1345-51	13
147	HDL und Arteriosklerose [Korrelation mit dem Auftreten kardiovaskulärer Ereignisse. 2010 , 39, 130-135	
146	Cardiac Complications and Management. 355-376	
145	Diabetes and cardiovascular mortality: from epidemiologic data to clinical trial evidence. 2010 , 73, 459-61	
144	[Hypertension, insulin resistance and chronic kidney disease in type 2 diabetes patients from South Kivu, DR Congo]. 2010 , 6, 520-5	16
143	Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme. 2011 , 18, 107-13	6

142	Cardiovascular risk factors and recommended lipid goals attainment among patients referred in a tertiary care lipid clinic. 2011 , 22, 412-7		14
141	Hypertension artfielle chez le sujet diabtique. 2011 , 6, 1-8		1
140	The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. 2011 , 5, 174-179		38
139	Establishing baseline criteria of cardio-ankle vascular index as a new indicator of arteriosclerosis: a cross-sectional study. 2011 , 11, 51		86
138	Genetic copy number variants in myocardial infarction patients with hyperlipidemia. 2011 , 12 Suppl 3, S23		24
137	Cardiovascular disease and dyslipidemia: beyond LDL. 2011 , 17, 861-70		53
136	Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus. 2011 , 12, 1429-38		15
135	Management of blood pressure in patients with diabetes. 2011 , 24, 863-75		26
134	Atlas of Atherosclerosis and Metabolic Syndrome. 2011 ,		5
133	Clinical prediction rule to estimate the absolute 3-year risk of major cardiovascular events after carotid endarterectomy. 2012 , 43, 1273-8		30
132	Multimodale Lipidtherapie bei Diabetes. 2012 , 7, 183-192		
131	Cholesterol goal attainment in hypertensive patients: the impact of metabolic syndrome components. 2012 , 10, 195-201		
130	[Identification of components of metabolic syndrome in Mexican patients hospitalized for acute ischemic coronary syndrome: a tool for prevention]. 2012 , 23, 32-8		
129	Hypertension: physiology and pathophysiology. 2012 , 2, 2393-442		145
128	1999-2009 Trends in prevalence, unawareness, treatment and control of hypertension in Geneva, Switzerland. <i>PLoS ONE</i> , 2012 , 7, e39877	3.7	88
127	Vascular Proteomics. 2013 ,		
126	L'apport de la mesure ambulatoire de la pression artfielle dans l'valuation du contrle tensionnel chez les diabtiques hypertendus : tude chez 60 diabtiques hypertendus traités, au Maroc. 2013 , 7, 521-524		
125	Quantitative proteomics analysis of high-density lipoproteins by stable 18O-isotope labeling. 2013 , 1000, 139-56		5

124	Contemporary management and attainment of cholesterol targets for patients with dyslipidemia in China. <i>PLoS ONE</i> , 2013 , 8, e47681	3.7	13
123	Factors related to coronary heart disease risk among men: validation of the Framingham Risk Score. 2014 , 11, E140		16
122	Racial disparities in cardiovascular risk factor control in an underinsured population with Type 2 diabetes. 2014 , 31, 1230-6		11
121	Risk factors of stroke in Western and Asian countries: a systematic review and meta-analysis of prospective cohort studies. 2014 , 14, 776		36
120	A novel gene regulator, pyrrole-imidazole polyamide targeting ABCA1 gene increases cholesterol efflux from macrophages and plasma HDL concentration. 2014 , 92, 509-21		12
119	Epidemiological studies of CHD and the evolution of preventive cardiology. 2014 , 11, 276-89		367
118	Treating hypertension in type 2 diabetes. 2014 , 15, 2131-40		9
117	Is nutritional labeling associated with individual health? The effects of labeling-based awareness on dyslipidemia risk in a South Korean population. 2016 , 15, 81		6
116	Framingham score, renal dysfunction, and cardiovascular risk in liver transplant patients. 2015 , 21, 812-22		26
115	A randomized, double-blind, placebo-controlled study of the effect of ezetimibe on glucose metabolism in subjects with type 2 diabetes mellitus and hypercholesterolemia. 2015 , 14, 40		14
114	Prevalence of Metabolic Syndrome and its Component in Patients with Acute Coronary Syndrome.. 2015 , 12, 42-48		1
113	Blood pressure reduction and control with fixed-dose combination perindopril/amlodipine: A Pan-Hellenic prospective observational study. 2015 , 16, 930-5		7
112	Effect of extractions from Stapf on hyperlipidemia in mice. 2015 , 9, 619-625		16
111	Spinal NF- κ B and chemokine ligand 5 expression during spinal glial cell activation in a neuropathic pain model. <i>PLoS ONE</i> , 2015 , 10, e0115120	3.7	26
110	Efficacy of Turmeric as Adjuvant Therapy in Type 2 Diabetic Patients. 2015 , 30, 180-6		58
109	The combination of nutraceutical and simvastatin enhances the effect of simvastatin alone in normalising lipid profile without side effects in patients with ischemic heart disease. 2016 , 11, 3-6		4
108	Managing hypertension in type 2 diabetes mellitus. 2016 , 30, 445-54		29
107	Type 2 Diabetes. 2016 ,		2

106	Blood pressure control in type 2 diabetic patients. 2017 , 16, 3	44
105	Low previous cardiovascular risk of patients with ST-elevation myocardial infarction. 2017 , 28, 413-416	1
104	Addition of estimated cardiorespiratory fitness to the clinical assessment of 10-year coronary heart disease risk in asymptomatic men. 2017 , 7, 30-37	8
103	Die Säulen der lipidsenkenden Therapie. 2017 , 11, 36-42	
102	Decreasing incidence of coronary heart disease in extreme obesity (BMI≥40)-A single centre experience. 2017 , 11, 435-444	2
101	Metabolic and Biochemical Stressors in Diabetic Cardiomyopathy. 2017 , 4, 31	13
100	mRNA expression of platelet activating factor receptor (PAFR) in peripheral blood mononuclear cells is associated with albuminuria and vascular dysfunction in patients with type 2 diabetes. 2018 , 136, 124-133	6
99	Influencing factors in quantitative measurement using activated platelet levels and platelet-activating capacity for the assessment of thrombosis in pre-metabolic syndrome and type 2 diabetes mellitus. 2018 , 20, 69-78	1
98	Investigation of HTTLPR gene polymorphism fluctuation in type II diabetes. 2018 , 4, 79-82	
97	Introduction of a web portal for an Individual Health Management and observational health data sciences. 2018 , 9, 183-196	1
96	Detection of acute periodontal pain from physiological signals. 2018 , 39, 095007	7
95	Predictors of glycemic control in type-2 diabetes mellitus: Evidence from a multicenter study in Ghana. 2018 , 1, 1-8	12
94	Effects of a nutraceutical multicomponent including bergamot (Citrus Bergamia Risso) juice on metabolic syndrome: A pilot study. 2018 , 11, 119-126	6
93	Atherosclerosis plaque area reduction: working hypothesis to prevent cardiovascular event. 2019 , 28, 907-914	1
92	A review on coronary artery disease, its risk factors, and therapeutics. 2019 , 234, 16812-16823	165
91	Sex hormones affect endothelial lipase-mediated lipid metabolism and atherosclerosis. 2019 , 18, 226	4
90	Latin American Consensus on the management of hypertension in the patient with diabetes and the metabolic syndrome. 2019 , 37, 1126-1147	17
89	Spiroergometrie in der erweiterten flugmedizinischen kardiovaskulären Beurteilung. 2019 , 26, 160-164	

88	Management of Hypertension. 2019 ,		4
87	Arterial Hypertension and Cardiovascular Risk. 2019 , 57-74		
86	Effectiveness of web-based personalised e-Coaching lifestyle interventions. 2019 , 27, 24-29		7
85	Association Between Hypertension in Healthy Participants and Zinc and Copper Status: a Population-Based Study. 2019 , 190, 38-44		12
84	Impact of Diabetes Mellitus on the Aortic Wall Changes as Atherosclerosis Progresses: Aortic Dilatation and Calcification. 2020 , 27, 509-515		3
83	The association between triglycerides and incident cardiovascular disease: What is "optimal"?. 2020 , 14, 438-447.e3		15
82	Blood pressure control in type 2 diabetes mellitus with arterial hypertension. The important ancillary role of SGLT2-inhibitors and GLP1-receptor agonists. 2020 , 160, 105052		6
81	Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review. 2020 , 75, 525-538		56
80	Correlates of autonomic nervous system function in a general population with special reference to HbA: The Nagahama study. 2020 , 163, 108126		2
79	Cardiac and Pulmonary Vascular Risk Stratification in Liver Transplantation. 2021 , 25, 157-177		2
78	Cardiovascular Disease Epidemiology and Risk Factors: General Concepts. 2021 , 1-22		
77	Mechanisms and Treatment of Dyslipidemia in Diabetes. 2021 , 23, 26		5
76	Structural Equation Modeling of a Global Stress Index in Healthy Soldiers. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	0
75	EVALUATION OF SERUM URIC ACID, SERUM MAGNESIUM AND LIPID PROFILES IN TYPE 2 DIABETES MELLITUS PATIENTS FOR THE RISK FACTOR OF CARDIOVASCULAR DISEASE.. 2021 , 6-9		
74	Update of the Brazilian Guideline for Familial Hypercholesterolemia - 2021. <i>Arquivos Brasileiros De Cardiologia</i> , 2021 , 117, 782-844	1.2	1
73	Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives to reduce SREBPs expression for the treatment of hyperlipidemia. <i>European Journal of Medicinal Chemistry</i> , 2021 , 221, 113522	6.8	1
72	Combination Therapy in Type 2 Diabetes.		2
71	Diabetes Mellitus and Cardiovascular Disease. 2011 , 227-252		1

70	Special Problems of the Diabetic Patient. 1990 , 145-157		5
69	Vaskuläre Erkrankungen. 1999 , 954-1093		1
68	Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. 1994 , 37, 889		7
67	[Pathophysiology of hypertension secondary to obesity]. <i>Archivos De Cardiologia De Mexico</i> , 2017 , 87, 336-344	0.2	3
66	A new molecular defect in the lecithin: cholesterol acyltransferase (LCAT) gene associated with fish eye disease.. <i>Journal of Lipid Research</i> , 1996 , 37, 35-44	6.3	7
65	Management of Hyperlipidemia in Diabetes Mellitus. <i>Endocrinology and Metabolism Clinics of North America</i> , 1992 , 21, 395-414	5.5	5
64	Serum cholesterol affects blood pressure regulation.		1
63	Hypertensive patients and diabetes: a high-risk population. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 32 Suppl 2, S1-8	3.1	4
62	Obesity, body fat distribution, and coronary artery disease. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2000 , 20, 96-108		62
61	European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2003 , 10, S1-S78		145
60	A DNA variant at the angiotensin-converting enzyme gene locus associates with coronary artery disease in the Caerphilly Heart Study. <i>Circulation</i> , 1995 , 91, 270-4	16.7	110
59	Diabetics with coronary disease have a prevalence of asymptomatic ischemia during exercise treadmill testing and ambulatory ischemia monitoring similar to that of nondiabetic patients. An ACIP database study. ACIP Investigators. Asymptomatic Cardiac Ischemia Pilot Investigators. <i>Circulation</i> , 1996 , 93, 2227-2237	16.7	47
58	The association of cardiovascular disease with impaired health-related quality of life among patients with type 2 diabetes mellitus. <i>Singapore Medical Journal</i> , 2014 , 55, 209-16	1.9	6
57	Effect of HDL-raising drugs on cardiovascular outcomes: a systematic review and meta-regression. <i>PLoS ONE</i> , 2014 , 9, e94585	3.7	43
56	Antiplatelet and Lipid-lowering Drugs in Hypertension. <i>European Cardiology Review</i> , 2014 , 9, 16-20	3.9	2
55	Prevalence of Dyslipidemic Phenotypes Including Hyper-apoB and Evaluation of Cardiovascular Disease Risk in Normocholesterolemic Type 2 Diabetic Patients. <i>Pakistan Journal of Biological Sciences</i> , 2006 , 9, 1536-1541	0.8	3
54	Apple as a Source of Dietary Phytonutrients: Bioavailability and Evidence of Protective Effects against Human Cardiovascular Disease. <i>Food and Nutrition Sciences (Print)</i> , 2014 , 05, 1234-1246	0.4	24
53	Prehypertension, Hypertension and Associated Cardiovascular Risk Factors among Adult Congolese Urban Dwellers: Results of the Vitaraa Study. <i>World Journal of Cardiovascular Diseases</i> , 2014 , 04, 390-398 ^o		3

- 52 Association of Pulse Pressure Difference and Diabetes Mellitus in Chinese People: A Cohort Study. *International Journal of General Medicine*, **2021**, 14, 6601-6608 2.3 0
- 51 Diabetes Mellitus and Vascular Disease Risk. **2000**, 193-212
- 50 Cholesterol, Triglycerides, and the Treatment of Hyperlipidemias. **2000**, 388-396
- 49 Diabetes Mellitus and Vascular Disease Risk. **2003**, 213-233
- 48 Dyslipoproteinämie. **2004**, 367-376
- 47 Obesity and Hypertension: Impact on Cardiovascular and Renal Systems. **2005**, 464-474
- 46 [Oxidized LDL and lipids as risk factors for ischemic heart disease in type 2 diabetes]. *Vojnosanitetski Pregled*, **2005**, 62, 529-36 0.1 1
- 45 Tserebrovaskulyarnye zabolevaniya i sakharnyy diabet 2 tipa. *Diabetes Mellitus*, **2006**, 9, 34-40 1.6 1
- 44 Dyslipidemia in the Metabolic Syndrome. **2006**, 215-242
- 43 Faktory sosudistogo riska, kognitivnyerasstroystva i izmeneniya kartiny MRT golovnogomozga u bol'nykh sakharnym diabetom 2 tipa. *Diabetes Mellitus*, **2006**, 9, 24-28 1.6
- 42 Hypertension: Impact of Echocardiographic Data on the Mechanism of Hypertension, Treatment, Options, Prognosis, and Assessment of Therapy. **2007**, 816-847
- 41 Management of Diabetic Dyslipidaemia. **2007**, 173-186
- 40 Dyslipidemia and Diabetes. **2007**, 405-416
- 39 [Do we reach target lipid levels in diabetic and non-diabetic patients with previous myocardial infarction?]. *Srpski Arhiv Za Celokupno Lekarstvo*, **2011**, 139, 30-6 0.2
- 38 Vaskuläre Erkrankungen. **2011**, 1055-1195
- 37 Assessment of Total Cardiovascular Risk in Hypertension: The Role of Subclinical Organ Damage. **2012**, 199-211
- 36 A Comparative Study on the Physiological Activities of *Auricularia* spp.. *Korean Journal of Food Science and Technology*, **2012**, 44, 350-355 2
- 35 The Anti-obesity Effect of 5 Herbal Formulas in High Fat Diet Induced Obese Mice. *Herbal Formula Science*, **2013**, 21, 44-52 2

34	Diabetes and Cardiovascular Risk: Epidemiologic Aspects. <i>Medical Science Symposia Series</i> , 1995 , 173-183		
33	Clustering of Cardiovascular Risk Factors. <i>Medical Science Symposia Series</i> , 1998 , 233-237		
32	Hypertensive Patients and Diabetes. <i>Journal of Cardiovascular Pharmacology</i> , 1998 , 32, S1-S8	3.1	8
31	Das metabolische Syndrom bei Frauen. 1998 , 9-16		
30	The unity of approaches to preventing coronary heart disease and cerebrovascular diseases. <i>Profilakticheskaya Meditsina</i> , 2015 , 18, 24	0.5	1
29	Effectiveness of Participatory Action-Oriented Training (PAOT) Methods for the Management Metabolic Syndrome in Korean Manufacture Workers for Three-years. <i>Korean Journal of Occupational Health Nursing</i> , 2016 , 25, 384-393		0
28	Gender and age associations of cardiovascular risk factors in patients with coronary heart disease. <i>Profilakticheskaya Meditsina</i> , 2017 , 20, 68	0.5	1
27	Primärprävention und Sekundärprävention des Hirninfarkts. <i>Springer Reference Medizin</i> , 2018 , 1-31	0	
26	An observational study to assess the prevalence of cardiovascular disease in type 2 diabetes mellitus patients on treatment with oral antidiabetic drugs, at a Tertiary care hospital, in Chennai. <i>International Journal of Pharma and Bio Sciences</i> , 2018 , 9,	1.2	
25	Diabetes and Cardiovascular Disease. 2019 , 709-730		
24	Primärprävention und Sekundärprävention des Hirninfarkts. <i>Springer Reference Medizin</i> , 2019 , 1-31	0	
23	Treating arterial hypertension in patients with metabolic syndrome. <i>Medicina Pro Praxi</i> , 2019 , 16, 23-26	0	
22	Primärprävention und Sekundärprävention des Hirninfarkts. <i>Springer Reference Medizin</i> , 2020 , 883-913	0	
21	Vaskuläre Erkrankungen. 2006 , 941-1073		
20	Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. <i>Diabetologia</i> , 1994 , 37, 585-591	10.3	
19	Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease. <i>Cmaj</i> , 1999 , 160, 1449-55	3.5	8
18	Multiple cardiovascular disease risk factors in Canadian adults. Canadian Heart Health Surveys Research Group. <i>Cmaj</i> , 1992 , 146, 2021-9	3.5	21
17	Summary of the 2007 European Society of Hypertension (ESH) and European Society of Cardiology (ESC) guidelines for the management of arterial hypertension. <i>Vascular Health and Risk Management</i> , 2007 , 3, 783-95	4.4	19

16	Plasma lipids, lipoproteins, and apolipoproteins in Nigerian diabetes mellitus, essential hypertension, and hypertensive-diabetic patients. <i>Journal of the National Medical Association</i> , 1995 , 87, 113-8	2.3	8
15	Serum lipid and lipoprotein levels in Ghanaians with diabetes mellitus and hypertension. <i>Journal of the National Medical Association</i> , 1997 , 89, 191-6	2.3	6
14	Prevalence of Coronary Artery Disease and the Associated Risk Factors in the Adult Population of Borujerd City, Iran. <i>The Journal of Tehran Heart Center</i> , 2019 , 14, 1-5	0.3	2
13	OUP accepted manuscript. <i>Brain</i> ,	11.2	
12	Development of small-molecule PCSK9 inhibitors for the treatment of hypercholesterolemia.. <i>Drug Discovery Today</i> , 2022 ,	8.8	3
11	Variability in the Control of Type 2 Diabetes in Primary Care and Its Association with Hospital Admissions for Vascular Events. The APNA Study.. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
10	Diabetes and Hypertension: What Is the Connection?. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2022 , 159-169	0.1	0
9	A Systematic Review and Meta-Analysis of Lipid Signatures in Post-traumatic Stress Disorder. <i>Frontiers in Psychiatry</i> , 2022 , 13,	5	0
8	WHO Non-Lab-Based CVD Risk Assessment: A Reliable Measure in a North Indian Population. 2022 , 17,		0
7	Optimisation of individual cardiovascular risk assessment in a German coronary artery disease cohort using a commercial test for genetic polymorphisms $\bar{\Delta}$ pilot study. 1-11		2
6	Recent Update on the Development of PCSK9 Inhibitors for Hypercholesterolemia Treatment. 2022 , 65, 15513-15539		1
5	Benefits of Intensified Reductions in Blood Glucose and in Blood Pressure for Patients with Type 2 Diabetes. 2022 , 104160		0
4	HDL Functions Current Status and Future Perspectives. 2023 , 13, 105		1
3	Hypertension in growth hormone excess and deficiency. 2023 , 217-247		0
2	Long-term Physical Activity Decreased the Risk of New-onset Hypertension in Type 2 Diabetes Mellitus Patients with Pre-hypertension: A Retrospective Cohort Study.		0
1	Hemodynamics and Arterial Stiffness in Response to Oral Glucose Loading in Individuals with Type II Diabetes and Controlled Hypertension. 2023 , 30, 175-181		0